<DOC>
	<DOCNO>NCT02549534</DOCNO>
	<brief_summary>Purpose : The purpose study test new way measure nerve damage woman breast cancer receive chemotherapy drug paclitaxel ( Taxol ) .</brief_summary>
	<brief_title>Early Detection Taxane-Induced Neuropathy Women With Breast Cancer</brief_title>
	<detailed_description>Purpose : The study four aim ; - The primary aim study determine whether woman receive either weekly Taxol ( 80-100 mg/m2 ) bi-weekly Taxol ( i.e. , dose-dense ; 175 mg/m2 ) show deficits axon-reflex mediated vasodilation ( AMV ) course six week Taxol therapy similar report patient diabetic genetically-inherited neuropathy . - The second aim study determine whether woman receive either weekly dose-dense Taxol develop change AMV develop sign &amp; symptom chemotherapy-induced peripheral neuropathy ( CIPN ) way support use change AMV early detection method small-fiber CIPN . - A third ( exploratory ) aim study determine whether change AMV detect study significantly correlate self-reported CIPN way would support use change AMV confirmatory marker CIPN . - A final ( exploratory ) aim study describe size axon reflex axon flare woman receive weekly Taxol start pre-Taxol anthracycline &amp; cyclophosphamide ( AC ) therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>Inclusion Criteria Women Breast Cancer : Age 1885 Able read , write , understand English Diagnosed histologicallyconfirmed , firsttime , nonmetastatic breast cancer ( stage IIIIB ) No prior exposure neurotoxic chemotherapy radiation time enrollment , Will receive weekly paclitaxel ( Taxol® generic paclitaxel , 80 100mg/m2 ) biweekly Taxol ( i.e. , dosedense ; 175 mg/m2 ) part cancer treatment regimen OR Will receive anthracycline cyclophosphamide ( AC ) follow weekly paclitaxel ( Taxol® generic paclitaxel , 80100mg/m2 ) biweekly Taxol ( i.e. , dosedense ; 175 mg/m2 ) part cancer treatment regimen ; Inclusion Criteria Healthy Controls : Aged 1885 Can read , write , understand English A history cardiovascular disease , hypertension , peripheral arterial/vascular disease ; Current use ( 1 ) medications/supplements control blood pressure ( e.g . betablockers , nitrate , calcium channel blocker , Phosphodiesterase5 ( PGE5 ) inhibitor ) ( 2 ) use statins cholesterol ; Suspected diagnose diabetes ( exception gestational diabetes ) ; Preexisting neuropathy , neuropathic pain , nerve injury ; Pain significant arthritis toe either foot ; Current skin disease fungal infection foot ; Significant damage deformity foot would alter blood flow make impossible measure/interpret finding ; Diagnosed suspect vasospastic disease Raynaud 's syndrome ; Current use tobacco/tobaccocontaining product ; Diagnosis restless leg syndrome movement disorder would prevent accurate data able collect . InStudy Restrictions : No caffeine alcoholcontaining product 12 hour prior study visit ; No food least one hour prior blood flow monitoring ; No nonsteroidal antiinflammatory drug ( NSAIDS ) 24 hour prior study visit unless directed physician . ( Note : These restriction design improve rigor quality data , noncompliance ground study exclusion ; adherence restriction monitor selfreport ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Taxane</keyword>
	<keyword>Neuropathy</keyword>
	<keyword>Chemotherapy-Induced Peripheral Neuropathy ( CIPN )</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Local skin heating</keyword>
	<keyword>Axon reflex</keyword>
	<keyword>Axon flare</keyword>
	<keyword>Total Neuropathy Score ( TNS )</keyword>
	<keyword>Laser Doppler Flowmetry ( LDF )</keyword>
	<keyword>Laser Speckle Contrast Imaging ( LSCI )</keyword>
	<keyword>Full-field laser perfusion imaging ( FLPI )</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Taxol</keyword>
</DOC>